FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
Level 5 - mechanism / opinion, no new human data
Narrative review and critical evaluation of existing trial data without systematic synthesis
PubMed 38478035 · doi:10.1007/s00737-024-01456-y
What was done
The authors conducted a critical evaluation of fezolinetant (Veozah), an FDA-approved non-hormonal neurokinin 3 receptor antagonist that targets the hypothalamic thermoregulatory center. The paper discusses efficacy and safety data from existing clinical trials, specifically referencing the Skylight 2 and Skylight 4 studies for moderate-to-severe menopausal vasomotor symptoms.
What was found
The abstract reports no numerical values, effect estimates, or statistical test results. It states qualitatively that data from the Skylight 2 and 4 trials demonstrate the safety and acceptability of fezolinetant with relatively few reported adverse effects, supporting its potential for treating menopausal vasomotor symptoms.
Why it matters
Fezolinetant offers a targeted, non-hormonal alternative for menopausal women with hot flashes and night sweats who cannot take or prefer to avoid traditional hormone therapy.
Limits
The abstract contains no quantitative metrics, effect sizes, sample sizes, or systematic review methodology. The authors note that comprehensive evaluations of safety, long-term effectiveness, and specific impacts on sleep patterns remain unaddressed and require prospective research.
Cited by
- supports Veozah is an FDA-approved medication for hot flashes that places stress on the liver.